InflaRx (NASDAQ:IFRX) Short Interest Up 15.0% in December

InflaRx (NASDAQ:IFRX) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 248,900 shares, an increase of 15.0% from the December 15th total of 216,500 shares. Based on an average daily volume of 264,900 shares, the days-to-cover ratio is presently 0.9 days.

InflaRx Price Performance

Shares of IFRX stock traded down $0.01 on Friday, hitting $2.54. The stock had a trading volume of 178,129 shares, compared to its average volume of 193,527. InflaRx has a 12-month low of $1.16 and a 12-month high of $2.82. The stock has a market cap of $149.56 million, a price-to-earnings ratio of -2.35 and a beta of 1.66. The business has a 50 day moving average of $2.30 and a 200 day moving average of $1.79.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of InflaRx in a research report on Thursday.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.